Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lamictal XR Monotherapy: Will Ex-U.S. Data Invalidate Historical Comparison?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA reviewers cite issues with the study design GSK used in its sNDA, but still find evidence of efficacy for partial seizures.

You may also be interested in...



Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials

GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.

Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials

GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.

FDA Encourages Sponsors Of Hypertension Drugs To Promote Their Cardiovascular Benefits

Final guidance allowing class-wide outcomes claims includes suggested language for both advertising and labeling.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel